PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.
about
Immune checkpoint blockade for hematologic malignancies: a reviewThe diagnosis and management of NK/T-cell lymphomas.Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report.Clinicopathological analysis of primary central nervous system NK/T cell lymphoma: rare and localized aggressive tumour among extranasal NK/T cell tumours.Follicular CD8+ T Cells: Origin, Function and Importance during HIV Infection.Recent advances in understanding and managing T-cell lymphoma.Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.EBV-associated primary nodal T/NK-cell lymphoma shows distinct molecular signature and copy number changes.A distinct subtype of Epstein Barr virus positive T/NK-cell lymphoproliferative disorder: Adult patients with chronic active Epstein Barr virus infection-like features.Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors.Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety.Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: A multicenter retrospective study.Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.Outlooks on Epstein-Barr virus associated gastric cancer.Cutaneous CD56+ T-cell lymphoma developing during pembrolizumab treatment for metastatic melanoma.Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma.Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinomaAggressive NK-Cell LeukemiaCurrent Immunotherapeutic Approaches in T Cell Non-Hodgkin LymphomasOncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphomaDrug response to PD-1/PD-L1 blockade: based on biomarkersNew developments in immunotherapy for lymphomaChallenges in Managing EBV-Associated T- and NK-Cell Lymphoproliferative Diseases
P2860
Q33645590-7AE66FC4-0F4D-4BB5-B78A-44C82DC486E7Q39243241-B0097CB2-C78C-4973-AEB5-FF088D21EA35Q39284101-959B9283-F4BF-40D7-8F91-4850D1BE1F04Q40103866-4C8F65BC-5178-4ADA-BCE8-A0EC7A00B27FQ40274020-008DDA85-177F-4DAA-BDD5-E48B66620A4FQ43119125-00E1C9B8-5C2C-47D5-AAC8-231FB644E852Q47131247-8B068CFE-71EC-4702-BF3C-2DF95139637DQ47329066-E6DC973B-AD8B-4D2F-A402-F0D17C1FC6A2Q47443241-AAFAC03B-DC53-45AA-9EE8-8C68C29BDCABQ47447684-CA78534B-EA51-4420-ADF2-D5CFC86C847BQ47565503-E728E646-1728-4C5B-86DC-F74B11A96864Q47855599-F9DC9CF6-C61E-46EE-9607-7D3EF1ACD252Q47952363-F1252C6A-7E0B-4F1B-93D4-D7AF396FD10EQ48114756-74B47C62-C794-43D9-8347-DD0C7F69E4EBQ48196748-4E71E1B0-C16F-4427-A2B3-512CD33F6DE1Q48517891-1E342F73-FADC-4B94-878D-D34F454B7A9AQ51804722-9CB5FBFB-B1FB-4551-B7E2-4484E23DDA03Q52718168-77306D89-0B3E-49CA-B56A-7FF99C980EE7Q52720624-6CA39123-E558-4A1B-B7A9-672736627254Q55013496-3B469AA3-E8BD-4191-929D-998BA2515328Q55094448-4CAC24C7-AA1C-40B5-BBED-91156764B3D1Q56929146-5B55F604-682B-4D4F-BB81-92DF3F39540DQ58576133-09F65A86-B0CB-4900-BBB7-6604EE66DD7BQ58723337-478B8653-27B3-4D52-A884-E0C936E993BEQ58742961-A02E38D5-C60F-42B3-A879-B1F2C41701ECQ58795673-DBC4059E-B430-4236-AF9B-FD7F82896D80Q58804962-8ADCACC0-8B2D-479E-B3A8-95D983CBED94Q59136496-AB3F3331-9507-4130-9B99-71A4FF18D408
P2860
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
PD1 blockade with pembrolizuma ...... mphoma failing l-asparaginase.
@en
type
label
PD1 blockade with pembrolizuma ...... mphoma failing l-asparaginase.
@en
prefLabel
PD1 blockade with pembrolizuma ...... mphoma failing l-asparaginase.
@en
P2093
P50
P1433
P1476
PD1 blockade with pembrolizuma ...... ymphoma failing l-asparaginase
@en
P2093
Benjamin Mow
Colin Phipps
Florence Loong
Jabed Iqbal
Li-Mei Poon
Pek-Lan Khong
Seok Jin Kim
Thomas S Y Chan
P304
P356
10.1182/BLOOD-2016-12-756841
P407
P577
2017-02-10T00:00:00Z